Medopad Raises $25M in Series B Funding to Further Develop its Digital Health Platform

Medopad, the U.K. startup that’s seeking to battle Alzheimer's with artificial intelligence...

Image: Public Domain Pictures

Medopad, the U.K. startup that’s seeking to battle Alzheimer's with artificial intelligence has raised $25m in series B funding. The funding round was led by Leaps by Bayer, an investment unit of Germany-based pharmaceutical company Bayer. Others participating in the round were investors NWS Holdings and Healthbox.

Read more AI Health Tech Firm Healx Raises $56 Million in Series B as It Looks to Accelerate Rare Disease Treatments

“Medopad has a bold mission to help people live their life to the fullest, one that requires long-term commitment and partnership to achieve,” said Medopad founder and CEO Dan Vahdat.

“We are delighted that Leaps by Bayer who participated in our Series A round have now become the lead investor in our Series B. We have found the ideal partner with the dedication to help us reach our vision of creating a world where each person lives their life to the fullest.”

With this funding round, Medopad has so far raised more than $50m. The company said it will use the money to boost its clinical research operations, including digital therapeutics (DTx) and digital biomarker discovery for treatment of conditions such as Alzheimer’s disease, diabetes and heart disease. It also plans to expand its international operations.

Medopad and Tencent are conducting trials to develop and validate algorithms that can potentially predict complications across a range of disease indications like Parkinson’s, Cancer and Heart Diseases. (Image: Medopad)

Some of the investment will be directed towards AI projects with life sciences firms such as Janssen, a Belgian business owned by US behemoth Johnson & Johnson. Medopad is also working with Tencent Medical AI Lab, an arm of Chinese tech giant Tencent.

“Our joint Tencent/Medopad lab uses AI techniques to solve clinical problems such as motion disorder syndromes such as Parkinson’s disease, cancer, psoriasis and the early detection of heart failure,” said Dr. Wei Fan, Executive Director of Tencent Medical AI Labs.

Founded in 2011, Medopad partners with scientists, technologists, and healthcare and pharmaceutical professionals to use artificial intelligence to collect and analyze data and then predict different medical conditions and outcomes, reports MobiHealthNews.

Digital biomarkers is a new category in medicine. It seeks to collect data and use digital technologies to predict risk and condition progression and diagnosis through digital technologies.

The platform is designed to save clinicians time in an effort to drive better diagnosis, care, and treatment for patients with chronic illnesses.

Sam Draper
November 7, 2019

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

CE Compliance for Wearable Light Patches - Interview with CareWear Corp

CareWear Corp is a privately held firm based in Nevada that...

Ynvisible and PragmatIC Join Forces to Offer Complete Flexible Display Modules

Ynvisible Interactive, a fast-growing IoT firm, and PragmatIC Semiconductor, a world leader in ...

South Korean CGM Receives Regulatory Approval

i-SENS, the South Korean maker of CGM said it has won regulatory approval for its CareSens Air.

This Wearable Detects Opioid Overdose and Automatically Calls for Help

In 2018, more than 115 people died from opioid overdose each day in the United States...
Discover more